OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, March 20, 2012

Controversies Continue in NCCN Ovarian Cancer Guidelines



Controversies Continue in NCCN Ovarian Cancer Guidelines

Medscape Medical News from the:  

National Comprehensive Cancer Network (NCCN) 17th Annual Conference

This coverage is not sanctioned by, nor a part of, the National Comprehensive Cancer Network.

From Medscape Medical News > Conference News

Controversies Continue in NCCN Ovarian Cancer Guidelines

Neoadjuvant Chemotherapy and CA-125 Reviewed


 
March 20, 2012 (Hollywood, Florida) — The ovarian cancer guidelines from the National Comprehensive Cancer Network (NCCN) address a number of ongoing controversies, according to a presenter here at the NCCN 17th Annual Conference.
 
"There have not been a lot of changes in the past year, but there are various areas of controversy in the guidelines," Robert Morgan, MD, from the City of Hope Comprehensive Cancer Center in Los Angeles, California, told Medscape Medical News at the conference.
One such controversy is about the usefulness of the biomarker CA-125 to monitor patients who have been treated with surgery and/or chemotherapy. Dr. Morgan called CA-125 the "most controversial" aspect of patient follow-up.......

open access: Critical Care | Supplements | 32nd International Symposium on Intensive Care and Emergency Medicine



Blogger's Note: critical care/'cancer' - numerous papers included in supplement
                                         ~~~~~~~~~~~~~

Critical Care | Supplements | 32nd International Symposium on Intensive Care and Emergency Medicine

Critical Care publishes selected research, proceedings and collections of thematic reviews as supplements. All articles published in supplements are subject to peer review and are free to access online. The journal also publishes supplements containing meeting abstracts.

Volume 16 Supplement 1

32nd International Symposium on Intensive Care and Emergency Medicine

  • Meeting abstracts
  • from 32nd International Symposium on Intensive Care and Emergency Medicine
  • Brussels, Belgium
  • 20-23 March 2012

Supreme court rules against Nestle unit (Prometheus Laboratories) on patent



Reuters: Supreme court rules against Nestle unit on patent


WASHINGTON | Tue Mar 20, 2012 10:32am EDT
(Reuters) - The Supreme Court ruled on Tuesday that Prometheus Laboratories could not patent a diagnostic method to observe changes in a patient's body to determine the best drug dosage for certain diseases, a decision that may affect the future of personalized medicine.......


Molecules to Medicine: “Conscience” Clauses versus Refusal: An Historical Perspective | Guest Blog, Scientific American Blog Network



Molecules to Medicine: “Conscience” Clauses versus Refusal: An Historical Perspective | Guest Blog, Scientific American Blog Network

"Refusal clauses deny our patients the care that they need. They are not benign clauses, euphemistically referred to as “conscience” clauses. They are, instead, unconscionable clauses, shirking the professional responsibility to put our patients first."

currently recruiting: Cryopreservation of Ovarian Tissue - Full Text View - ClinicalTrials.gov



Cryopreservation of Ovarian Tissue - Full Text View - ClinicalTrials.gov

This study is currently recruiting participants.
Verified March 2012 by Weill Medical College of Cornell University

First Received on February 16, 2012.   Last Updated on March 19, 2012   History of Changes

The Cause and Effect of Migraines



Blogger's Note:
due to hormonal flucuations and onset of female cancers, it is interesting that the migraine connection (eg symptoms, neurology, pathology (?)) has not been a topic of wider discussion/research/debate in cancer research
             ~~~~~~~~~~~~~~~~~~~~~~~

The Cause and Effect of Migraines

"“Hormonal changes are a big contributor to the higher female incidence,” said Michael A. Moskowitz, MD, Professor of Neurology at Harvard Medical School at the Massachusetts General Hospital in Boston. “There are lines of evidence that support this from lab to clinical evidence and a decrease (although not abolished) incidence in post-menopausal females.”"

open access: Opinion: Academic Publishing Is Broken | The Scientist (including commentaries)



Opinion: Academic Publishing Is Broken | The Scientist

abstract: Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery - Variability of Poly (ADP-Ribose) Polymerase Activity.



Wiki:  Poly ADP ribose polymerase: Poly (ADP-ribose) polymerase (PARP) is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death.

                   ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

 Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery - Variability of Poly (ADP-Ribose) Polymerase Activity.

Abstract

Purpose: 

The aim of this study was to evaluate the feasibility of phase 0 trials in the setting of a routine surgical procedure. Logistic considerations, tissue sampling and handling, and variability of a biomarker during surgery, in here activity of poly(ADP-ribose) polymerase, were evaluated. 

Experimental design: 

Patients with highly suspicious or proven diagnosis of advanced ovarian cancer, planned for debulking surgery were asked to allow sequential tumor biopsies during surgery. Biopsies were frozen immediately and poly (ADP-ribose) polymerase activity was measured subsequently. 

Results: 

Baseline biopsies were obtained from eight patients after a median time of 88 minutes (minimum of 50 to maximum of 123 minutes). Second and third biopsies were obtained after a median of 60 (32-96) and 101 (79-130) minutes, respectively. Mean tumor load was 44% (5%-100%), with a cellular viability of 98% (85%-100%). Median baseline PARP activity was 1035 pg/ml (range: 429-2663 pg/ml). The observed inter-patient variability at baseline was large: standard deviation was 769 before and 0.59 after natural log transformation. 

Conclusions: 
Conducting phase 0 trials during surgery seems to be feasible in terms of logistic considerations. In preparation of a phase 0 trial during surgery, a feasibility study like this should be conducted to rule out major interactions of the surgical intervention with respect to the targeted biomarker.

abstract: [Assessment of health-related quality of life in cancer outpatients treated with chemotherapy] Japanese study



[Assessment of health-related quality of life in cancer outpatients treated with chemotherapy].


Abstract
Purpose: 

Few studies have been conducted to elucidate the health-related quality of life(HR-QOL) of cancer outpatients treated with chemotherapy. In this study, we attempted to determine the physical and psychological distress of cancer outpatients treated with chemotherapy.

Methods:
Two-hundred and ninety-six outpatients with various malignancies, including malignant lymphoma, and esophageal, gastric, pancreatic, colon, lung, breast, ovarian, uterine and skin cancers, were investigated using the Japanese version of the M. D. Anderson symptom inventory from March through June 2010 in Tokyo Medical University Hospital.

Results:
The results of the survey questionnaire indicated that 59 patients suffered from fatigue, 56 experienced numbness or tingling, 48 felt drowsy, 39 had low moods, 40 felt distressed, 38 had no appetite, 38 had dry mouth, 37 were in pain, 37 had disturbed sleep, 31 had shortness of breath, 24 had nausea, 17 suffered from vomiting, and 13 patients had memory problems. Furthermore, these symptoms interfered with work(65 patients), walking(56 patients), mood(52 patients), life enjoyment(49 patients), general activity(49 patients), and relationships with other people(42 patients). Medications prescribed for HR-QOL control were non-steroidal anti-inflammatory drugs (93 patients), morphine(32 patients), and adjuvant analgesics(47 patients).

Conclusion:
The present findings may help in the development of management strategies for physical and psychological distress, and improve HR-QOL of cancer outpatients treated with chemotherapy.


abstract: Pediatric and Young Adult Patients and Oncofertility.



Pediatric and Young Adult Patients and Oncofertility.:
Pediatric and Young Adult Patients and Oncofertility.

Abstract
OPINION STATEMENT:


With improving survival rates for pediatric and young adult cancer patients, considerations regarding the long-term effects of therapy have become more important. Cancer therapies are known to pose reproductive risks, though the effects may be unpredictable. All at-risk patients should have a discussion about potential treatment-related infertility before the onset of cancer therapy, and should be offered appropriate fertility preservation options. Embryo and sperm cryopreservation are considered standard therapy, though oocyte cryopreservation is gaining acceptance. Ovarian tissue cryopreservation, while still experimental, is showing great promise. It is the only option currently available to prepubertal girls. No fertility preservation options exist for prepubertal boys though some institutions may offer experimental testicular tissue cryopreservation.


abstract: Small cell carcinoma of the ovary of hypercalcemic type: a case report



Small cell carcinoma of the ovary of hypercalcemic type: a case report

 Abstract

The authors report a case of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), in a mother and daughter and discuss the possibility of a heritable risk.

Both mother and daughter were treated at the same institution (Kentucky)  for SCCOHT.

A 23-year-old woman presented with hypercalcemia 4 months after giving birth to her daughter. She was diagnosed as having SCCOHT. Despite surgery, chemotherapy, and radiation, she died of the disease 11 months after diagnosis.

Eleven years later, her daughter presented with a histologically and immunophenotypically identical SCCOHT tumor. She received postoperative chemotherapy and radiation but, eventually, relapsed and died of the disease at 27 months after the initial diagnosis.  

Small cell carcinoma of the ovary, hypercalcemic type, is an uncommon and aggressive malignancy that occurs in young women, which is associated with a solid ovarian tumor and hypercalcemia. Despite aggressive multimodality treatment, most patients die within 2 years of diagnosis. Genetic counseling, sonographic ovarian surveillance and serum calcium monitoring at early age, and even prophylactic oophorectomy should be considered for surviving at-risk family members.

abstract: Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: A 10-year experience and reappraisal of its clinical utility



Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: A 10-year experience and reappraisal of its clinical utility



Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: A 10-year experience and reappraisal of its clinical utility.

Abstract

OBJECTIVE:

To evaluate the utility of peritoneal washing cytology (PWC) for detecting occult primary peritoneal carcinoma in patients with BRCA1 or BRCA2 mutations, we reviewed PWCs obtained during risk-reducing salpingo-oophorectomy (RRSO) from 117 patients at our institution and correlated the results with surgical pathology findings.........

abstract: Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer



Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.


Abstract

OBJECTIVE: 

To identify factors that increase the risk of neutropenic events in women with advanced ovarian carcinoma receiving initial chemotherapy.

METHODS: 
Multi-center retrospective study of women with FIGO stage III-IV epithelial ovarian cancer treated postoperatively with multi-agent intravenous chemotherapy 1995-2008.......

CONCLUSION:
While SN is fairly common, FN occurs infrequently in women with EOC undergoing taxane and platin-based chemotherapy and primary prophylactic growth factor support is not indicated. However, women older than 60 years of age receiving non-carboplatin containing regimens are at higher risk for FN and warrant closer surveillance.


abstract: Primary Chemotherapy for Inoperable Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without Delayed Debulking Surgery



Int J Gynecol Cancer. 2012 Mar 15

Abstract

OBJECTIVE:

To describe the outcome of primary chemotherapy for women with advanced-stage epithelial ovarian or primary peritoneal cancer and delayed surgery when optimal debulking surgery cannot be achieved at diagnosis.......

New NCCN Guidelines on Cancer Care for Teens, Young Adults



New NCCN Guidelines on Cancer Care for Teens, Young Adults

March 19, 2012 (Hollywood, Florida) — Since 1975, adults older than 44 years and children younger than 15 years have had significant improvements in cancer survival in the United States, but there has been no such improvement seen in the survival of adolescents and young adults (aged 15 - 39 years) with cancer, according to new research presented here at the National Comprehensive Cancer Network (NCCN) 17th Annual Conference......

JCO abstract: Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers (185delAG, 5382insC, 6174delT)



Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers

Purpose 
Mutations in BRCA1/2 dramatically increase the risk of both breast and ovarian cancers. Three mutations in these genes (185delAG, 5382insC, and 6174delT) occur at high frequency in Ashkenazi Jews. We evaluated how these common Jewish mutations (CJMs) affect cancer risks and risk reduction. 

Methods 
Our cohort comprised 4,649 women with disease-associated BRCA1/2 mutations from 22 centers in the Prevention and Observation of Surgical End Points Consortium. Of these women, 969 were self-identified Jewish women. Cox proportional hazards models were used to estimate breast and ovarian cancer risks, as well as risk reduction from risk-reducing salpingo-oophorectomy (RRSO), by CJM and self-identified Jewish status. 

Results 
Ninety-one percent of Jewish BRCA1/2-positive women carried a CJM. Jewish women were significantly more likely to undergo RRSO than non-Jewish women (54% v 41%, respectively). Relative risks of cancer varied by CJM, with the relative risk of breast cancer being significantly lower in 6174delT mutation carriers than in non-CJM BRCA2 carriers. No significant difference was seen in cancer risk reduction after RRSO among subgroups

Conclusion 
Consistent with previous results, risks for breast and ovarian cancer varied by CJM in BRCA1/2 carriers. In particular, 6174delT carriers had a lower risk of breast cancer. This finding requires additional confirmation in larger prospective and population-based cohort studies before being integrated into clinical care.

The Chinese-German Journal of Clinical Oncology - abstract: Clinical significance of CA125 regression in chemotherapy of advanced ovarian cancer



The Chinese-German Journal of Clinical Oncology

Abstract

Objective  

The aim of this study was to compare the serum CA125 regression in advanced ovarian carcinoma patients treated with paclitaxel/platinum (TP) and platinum/epirubicin/ifosfamide (PAC) during early chemotherapy. The relationship between survival and CA125 regression during first line chemotherapy was evaluated.

Conclusion  

There isn’t significant difference in serum CA125 regression between patients who are treated with PAC or PT during early chemotherapy. CA125 half-life and nadir CA125 concentration are independent prognostic factor in advanced ovarian cancer.

Monday, March 19, 2012

MabCure Announces Agreement with the City University of New York Center for Advanced Technology to Validate and Evaluate Its Monoclonal Antibodies as Ovarian Cancer Diagnostic Reagents - MarketWatch



MabCure Announces Agreement with the City University of New York Center for Advanced Technology to Validate and Evaluate Its Monoclonal Antibodies as Ovarian Cancer Diagnostic Reagents - MarketWatch

abstract: Coordination of Breast Cancer Care Between Radiation Oncologists and Surgeons: A Survey Study



Coordination of Breast Cancer Care Between Radiation Oncologists and Surgeons: A Survey Study:

Purpose: 

To assess whether radiation oncologists and surgeons differ in their attitudes regarding the local management of breast cancer, and to examine coordination of care between these specialists.

Conclusions:

Despite the widespread availability of tumor boards, a substantial minority of radiation oncologists indicated other providers failed to include them in the breast cancer treatment decision-making process early enough. Earlier inclusion of radiation oncologists may influence patient decisions, and interventions to facilitate this should be considered.

abstract: Role of Definitive Radiation Therapy in Carcinoma of Unknown Primary in the Abdomen and Pelvis



Role of Definitive Radiation Therapy in Carcinoma of Unknown Primary in the Abdomen and Pelvis

 Objectives

Carcinoma of unknown primary (CUP) in the abdomen and pelvis is a heterogeneous group of cancers with no standard treatment. Considered by many to be incurable, these patients are often treated with chemotherapy alone. In this study, we determined the effectiveness of radiation therapy in combination with chemotherapy in patients with CUP in the abdomen and pelvis.

Patients and Methods

Medical records were reviewed for 37 patients with CUP treated with radiation therapy for disease located in the soft tissues and/or nodal basins of the abdomen and pelvis at the University of Texas M.D. Anderson Cancer between 2002 and 2009. All patients underwent chemotherapy, either before or concurrent with radiation therapy. Patients were selected for radiation therapy on the basis of histologic type, disease extent, and prior therapy response. Twenty patients underwent definitive radiation therapy (defined as radiation therapy targeting all known disease sites with at least 45 Gy) and 17 patients underwent palliative radiation therapy. Only 6 patients had surgical resection of their disease. Patient and treatment characteristics were extracted and the endpoints of local disease control, progression-free survival (PFS), overall survival (OS), and treatment-related toxicity incidence were analyzed.

Results

The 2-year PFS and OS rates for the entire cohort were 32% and 57%, respectively. However, in patients treated with definitive radiation therapy, the rates were 48% and 76%, and 7 patients lived more than 3 years after treatment with no evidence of disease progression. Nevertheless, radiation-associated toxicity was significant in this cohort, as 40% experienced Grade 2 or higher late toxicities.

Conclusions

The use of definitive radiation therapy should be considered in selected patients with CUP in the soft tissues or nodal basins of the abdomen and pelvis.

Waiting for medicine’s black swans - CMAJ



Waiting for medicine’s black swans

"Over a decade has passed since the medical world quivered with anticipation at the completion of the Human Genome Project. For the most part, though, those heady days have been replaced by the sobering realization that the path from knowledge to product is riddled with potholes.
Time, tight budgets and delivery complications have emerged as major ruts in the drive toward the pot of therapeutic gold that was promised for the end of road....."

"....One possible solution was presented by Dr. Anil K. Sood, professor of gynecologic oncology in the Division of Surgery at the University of Texas MD Anderson Cancer Center in Houston. Sood’s research with mouse models of ovarian and colorectal cancer indicated that high-density lipoprotein nanoparticles (so-called “good” cholesterol) could be used to deliver small interfering RNAs (siRNAs) to specific gene targets.....

Association for Psychological Science (Harvard): Is modern medicine ill with dehumanization?



Is modern medicine ill with dehumanization?

New article offers a diagnosis, unveils its causes, and prescribes a humanizing cure

"Anyone who has been admitted into a hospital or undergone a procedure, even if cared for in the most appropriate way, can feel as though they were treated like an animal or object," says Harvard University psychologist and physician Omar Sultan Haque. Health care workers enter their professions to help people; research shows that empathic, humane care improves outcomes. Yet dehumanization is endemic. The results can be disastrous: neglect of necessary treatments or prescription of excessive, painful procedures or dangerous drugs.

What are the causes and effects of dehumanization in medicine? And what can be done about it? In Perspectives in Psychological Science, a journal of the Association for Psychological Science, Haque and co-author Adam Waytz at the Kellogg School of Management of Northwestern University synthesize diverse literatures to distinguish when dehumanization is useful from when it is not. Then they recommend "simple, cheap, and effective" changes to "make medical institutions more humane and ethical, as well as efficacious in the service of improved health," says Haque.

The structures of institutions and the psychological demands of providing care can cause professionals to treat patients as less than human. "Deindividuation"—doctors as a sea of white coats; patients as half-naked bodies in smocks, identified by their disease or procedure ("the gallbladder in Room 38")—allows staffs to avoid taking responsibility for each patient. "Impaired patient agency" refers to medical staffs' treatment of patients as incapable of planning their own care, which is both infantilizing and demoralizing. "Dissimilarity"—hierarchies of power, differences of race, class, and gender between staff and patients—have roots outside the hospital. Nevertheless, they cause miscommunication and alienation, even maltreatment. None of these practices serves good medical care.

More complex are dehumanizing practices that may aid care. Diagnosis and treatment might necessitate "mechanization"—breaking the body into organs and systems. Scaling back empathy can diminish staff stress and burnout. Even moral disengagement can be adaptive. From giving a shot to slicing into the flesh to perform surgery, medical care often requires inflicting pain or invading the boundaries of the body in violation of deeply held human taboos. And patients may die after even the best of care. For the professional, guilt could be paralyzing.

Still, the authors argue, dehumanization is useful only in "specific contexts," such as acute care. Waytz says, "Dehumanization's functionality varies wildly across specialities from pediatrics to orthopedic surgery, so future research is needed to determine when dehumanization is most prevalent and most detrimental." In the meantime, the authors offer numerous humanizing fixes: Call patients by name, not numbers; discourage labeling people as diseases; personalize hospital rounds and pre-surgical preparation; eliminate opaque surgical masks; affix photos to CT scans and biopsies. Include patients in care planning. Let them choose their gowns—and design those gowns so they're no so humiliating. Increase physician diversity and hire people with good social skills. And, for med schools, perhaps most radical: Eliminate the "white-coat ceremony" when graduates don the mufti of the elect.

Finally, "we should train medical professionals to think of themselves as mortal – sharing a common humanity and vulnerability with their patients," says Haque. Although dehumanization can be useful, "even functional dehumanization should be viewed like a potent, salutary, but dangerous drug that can have disastrous side-effects" when overprescribed.

Incidentalome: Accidental Gene Findings You May Not Want To Know | CommonHealth



Incidentalome: Accidental Gene Findings You May Not Want To Know | CommonHealth

open access: Ten problematical issues identified by pathology review for multidisciplinary gynaecological oncology meetings -- McCluggage 65 (4): 293 -- Journal of Clinical Pathology



Ten problematical issues identified by pathology review for multidisciplinary gynaecological oncology meetings

  • Accepted 16 August 2011
  • Published Online First 19 October 2011   
  • J Clin Pathol 2012;65:293-301 doi:10.1136/jclinpath-2011-200352

Take-home message

Pathology review of gynaecological cancer specimens is often carried out as part of the working of gynaecological oncology multidisciplinary team meetings. Some errors are interpretational errors while others are non-interpretational but may result in the incorrect information being relayed to the clinician. Studies have identified more numerous and clinically significant diagnostic discrepancies in the field of gynaecological oncology than in other areas of pathology.

Healthcare Economist: (NY Times) Why are there no doctor reviews on the web?



Why are there no doctor reviews on the web?:

The N.Y. Times has an interesting article citing a number of reasons why there are no good websites with doctors reviews on the web.  There are some ratings websites (HealthGradesRateMDs, Angie’s List, Yelp), but the listings are often sparse, with few contributors and little of substance.)
For one, physicians don’t like them.
Several years ago, a physician reputation management service called Medical Justice developed a sort of liability vaccine. Doctors would ask patients to sign an agreement promising not to post about the doctor online; in exchange, patients would get additional privacy protections.

blog: The Patient Will Rate You Now



The Patient Will Rate You Now:
By Bob Wachter, MD

These days, I’d never consider trying a new restaurant or hotel without reading the on-line ratings on TripAdvisor or Yelp. I seldom even bother with professional restaurant or travel critics.
Until recently, there was little patient-generated information about doctors, practices or hospitals to help inform patient decisions. But that is rapidly changing, and the results may be every bit as transformative as they have been in traditionally consumer-centric industries like hospitality. Medicine has never thought much of the wisdom of crowds, but the times, as the song goes, they are a-changin’.

abstract: Variation in thromboembolic complications among patients undergoing commonly performed cancer operations



Variation in thromboembolic complications among patients undergoing commonly performed cancer operations

Compared with breast cancer, the incidence of VTE ranged from a 1.31-fold increase in VTE associated with gastrectomy to a 2.68-fold increase associated with hysterectomy.

Oral Cancer Drugs Not Effective When Mixed With Some Other Medications - MediLexicon



Oral Cancer Drugs Not Effective When Mixed With Some Other Medications - MediLexicon

...........The cancer drugs which the researchers studied are called oral kinase inhibitors. They included:
  • imatinib (Gleevec®)
  • erlotinib (Tarceva®)
  • dasatinib (Sprycel®)
  • everolimus (Afinitor®)
  • lapatinib (Tykerb®)
  • nilotinib (Tasigna®)
  • pazopanib (Votrient®)
  • sorafenib (Nexavar®)
  • sunitinib (Sutent®)
The medications that pose a threat to the effectiveness of oncology drugs are:
  • calcium channel blockers
  • some antibiotics
  • antifungal agents
  • steroids
  • proton pump inhibitors..........

Myriad, Prometheus Continue to Defend Diagnostic Patents while Others Urge More Licensing (BRCA patients)






Sunday, March 18, 2012

American College of Rheumatology: Patient Education - Fibromyalgia



Patient Education - Fibromyalgia

Faculty of Health Science - News - New Blood Test for Early Cancer Detection Developed by Ben-Gurion University of the Negev Researchers



Faculty of Health Science - News - Cancer_detection


New Blood Test for Early Cancer Detection Developed by Ben-Gurion University of the Negev Researchers



90 Percent Detection Rate in Clinical Tests for Multiple Types of Cancers
A simple blood test is being developed by researchers at Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center in Beer-Sheva, Israel that may provide early detection of many types of cancer.
Prof. Joseph Kapelushnik of BGU’s Faculty of Health Sciences and his team developed a device that illuminates cancer cells with less than a teaspoon of blood. The test uses infrared light to detect miniscule changes in the blood of a person who has a cancerous growth somewhere, even before the disease has spread. Various molecules released into the bloodstream cause it to absorb infrared light slightly differently compared to that of healthy people.  
In the latest clinical trial with 200 patients and a control group, the test identified specific cancers in 90 percent of the patients and found other types of cancer, as well.  The researchers are focused on detection of common cancers, such as lung and ovarian cancer. 
Doctors believe that it is critical to increase cancer detection in early stages to prevent the need for long, difficult and costly treatments in more advanced stages.
“This is still research in the early stages of clinical trials,” clarifies Prof. Joseph Kapelushnik, who is also head of the Department of Pediatric Hemato-Oncology at Soroka hospital. 
“But the purpose is to develop an efficient, cheap and simple method to detect as many types of cancers as possible. We want to be able to detect cancer while a patient is still feeling good, before it has a chance to metastasize, meaning fewer treatments, less suffering and many more lives saved.”
More clinical trials will be conducted in the next 18 months.
Publish date: 26/02/2012

Seth's Blog: The ironic truth about sincerity



Seth's Blog: The ironic truth about sincerity:

No one cares how much you care.
That salesperson who will surely die if he doesn't close this sale, that painter who is sweating blood to get her idea on the canvas, that student who just pulled an all-nighter...
In fact, we're hyper alert to the appearance of caring. We want to do business with people who appear to care, who appear to bring care and passion and dedication to their work. If the work expresses caring, if you consistently and professionally deliver on that expression, we're sold.
The truth is that it's what we perceive that matters, not what you bring to the table. If you care but your work doesn't show it, you've failed. If you care so much that you're unable to bring quality, efficiency and discernment to your work, we'll walk away from it.
And the irony? The best, most reliable way to appear to care when it matters--is to care.

Saturday, March 17, 2012

WSJ to Biotech: "You're All Going To Die." Thanks - Now Let's Keep Fighting. - Forbes (worth reading)



WSJ to Biotech: "You're All Going To Die." Thanks - Now Let's Keep Fighting. - Forbes

"Friday’s WSJ features a brutally – I mean brutally — frank article about the dismal state of biotech financing.  There are few revelations (certainly not for those readers of this column who I know follow the space closely), and unfortunately, few patches of sunlight.   This clip from Play It Again, Sam pretty much captures the tone.
The crisis in financing is having a chilling effect on biomedical innovation.  As discussed in my last column, the main problem in our industry is that the sheer cost of drug development has become almost prohibitively expensive, effectively pricing almost everyone but the largest companies out of the market............"

"..........In the land of digital health, I also worry that there are a lot of developers who I don’t think really understand the gravitas of illness and disease.  For many of these folks, wellness is best envisioned as a fun and entertaining diversion, one that should be pursued with enthusiasm and characterized by delight.  Yet this whole idea of “gamefication” – while obviously both popular and fundable – doesn’t really connect with so much of what I’ve seen as a physician (and you don’t have to be a physician to understand the distinction – clearly, Jamie Heywood is an it-getter).
Perhaps when you’re 22, wellness is a game, but for most of the patients I recall in internal medicine, it really was anything but; patients have very serious, often existential concerns about their health, and about their ability to work and to provide.  What these patients want, expect, and deserve is serious engagement – and not some dipshit app........."

ICGC Data Portal - search using MSH2 gene as an example



ICGC Data Portal (search results MSH2)

United States - Ovarian Cancer | International Cancer Genome Consortium



United States - Ovarian Cancer | International Cancer Genome Consortium

Project Summary
The National Cancer Institute and the National Human Genome Research Institute launched The Cancer Genome Atlas program to create a comprehensive atlas of the genomic changes involved in more than 20 common types of cancer. This large-scale, high-throughput effort is being carried out by a network of more than 100 researchers at many organizations across the Unitred States. The overarching goal of TCGA is to further scientific understanding of the genomic changes in cancer, thereby improving the ability to diagnose, treat and prevent this devastating disease. All data generated by the TCGA research network are made rapidly available to the research community through the TCGA Data Portal.

Principal Investigators
TCGA Program Directors: Kenna Shaw, Ph.D., (NCI) and Brad Ozenberger, Ph.D., (NHGRI)
Biospecimen Core Resources (BCRs)
Julie Gastier-Foster, Ph.D.
Robert Penny, M.D., Ph.D.
Genome Characterization Centers (GCCs)
Stephen Baylin, M.D.
Rui Chen, Ph.D.
Lynda Chin, M.D.
Stacey Gabriel, Ph.D
Richard Gibbs, M.D, Ph.D.
Neil Hayes, M.D., M.P.H.
Raju Kucherlapati, Ph.D.
Peter Laird, Ph.D.
Jason Lieb, Ph.D.
Marco Marra, Ph.D.
Matthew Meyerson, M.D., Ph.D.
Chuck Perou, Ph.D.
Jonathan Seidman, Ph.D
David Wheeler, Ph.D.
Genome Sequencing Centers (GSCs)
Richard Gibbs, Ph.D.
Eric Lander, Ph.D.
Richard Wilson, Ph.D.
Data Coordinating Center (DCC)
John Greene, Ph.D., Project Director
Genome Data Analysis Centers (GDACs)
Christopher Benz, M.D
Lynda Chin, M.D.
Gaddy Getz, Ph.D.
David Haussler, Ph.D.
Neil Hayes, M.D., M.P.H.
Marc Ladanyi, M.D
Gordon Mills, M.D., Ph.D.
Chris Sander, Ph.D.
Ilya Shmulevich, Ph.D.
Terrence Speed, Ph.D.
Paul Spellman, Ph.D.
John Weinstein, M.D., Ph.D.
W.K. Alfred Yung, M.D.
Wei Zhang, Ph.D.

Australia - Ovarian Cancer | International Cancer Genome Consortium



Australia - Ovarian Cancer | International Cancer Genome Consortium

 

Project Summary
The primary aims sequence largely paired primary and recurrent ovarian tumors primarily drawn from a population based cohort study, the Australian Ovarian Cancer Study. The studies will define the somatic genomic abnormalities in primary ovarian tumours and insights into the molecular drivers of primary and acquired platinum resistance.

Principal Investigators
Institute for Molecular Bioscience
• Sean M. Grimmond (overall lead)
• David Miller
• Conrad Leonard
• Nicola Waddell
• Peter Wilson
• John V. Pearson
• Karin Kassahn
Peter MacCallum Cancer Centre
• David Bowtell (ovarian cancer lead)
• Dariush Etemadmoghadam
Westmead Millennium Institute for Medical Research
• Anna de Fazio
Queensland Institute for Medical Research
• Adèle Green
• Georgia Chenevix-Trench
• Penelope Webb
• David Whiteman
• David Purdie

March 15th update: Version 8 ICGC data protal (updates)International Cancer Genome Consortium



International Cancer Genome Consortium

 ICGC Goal: To obtain a comprehensive description of genomic, transcriptomic and epigenomic changes in 50 different tumor types and/or subtypes which are of clinical and societal importance across the globe

  • 15/March/2012 - The ICGC Data Coordination Center (DCC) is pleased to announce the release of Version 8 of the ICGC data portal.

    This update includes first data releases from France’s Liver Cancer project, Germany’s Pediatric Brain Cancer project, and the United Kingdom’s Myelodysplastic Syndrome Project. Also included are new submissions from the Australian Pancreatic Cancer project, the Canadian Pancreatic Cancer project, the Japanese Liver Cancer project, and the United Kingdom Breast Cancer (Triple Negative) project.

    This data adds to previous data releases from the Chinese Gastric Cancer project, the Spanish Chronic Lymphocytic Leukemia project and submissions from The Cancer Genome Atlas in the United States, which has contributed information on about 10 types of cancer affecting the blood, brain, breast, colon, kidney, lung, ovaries, rectum, stomach and uterus.

    In total, 600 newly-available cancer datasets are provided in this release, with the ICGC data portal now containing data from 3,561 cancer genomes.

Updates

  • Currently, the ICGC has received commitments from funding organizations in Asia, Australia, Europe and North America for 47 project teams in 15 jurisdictions to study over 21,000 tumor genomes. Projects that are currently funded are examining tumors affecting the bladder, blood, bone, brain, breast, cervix, colon, head and neck, kidney, liver, lung, oral cavity, ovary, pancreas, prostate, rectum, skin, soft tissues, stomach, thyroid and uterus. Over time, additional nations and organizations are anticipated to join the ICGC. The genomic analyses of tumors conducted by ICGC members in Australia and Canada (pancreatic cancer), China (gastric cancer), France (liver cancer), Germany (brain cancer), Japan (liver cancer), Spain (blood cancer), the UK (blood, breast, lung and skin cancer) and the USA (blood, brain, breast, colon, kidney, lung, ovarian, rectal, stomach and uterine cancer) are now available through the Data Coordination Center housed on the ICGC website at www.icgc.org.

abstract: Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.



Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.


Abstract

PURPOSE:

This phase I trial evaluated intraperitoneal (IP) pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.

The (U.S.) overnment’s Assault on Women’s Health | e-Patients.net



The Government’s Assault on Women’s Health | e-Patients.net

"I’m a little confused… I’m not sure where the U.S. Constitution guaranteed the government’s right to interfere with the doctor/patient relationship. Nowhere in this historic document could I find anything about the government’s right to dictate how women’s health and reproductive health (but not men’s) are areas appropriate to government interference. (You won’t find it in any state’s Constitution either.)
Yet that’s not stopping government intervention into the doctor-patient relationship from state to state, completely oblivious to the lack of jurisdiction to interfere in this professional relationship. Imagine if the government started wanting to regulate how people practiced their faith?......"

abstract: Does Significant Medical Comorbidity Negate the Benefit of Up-front Cytoreduction in Advanced Ovarian Cancer?



Does Significant Medical Comorbidity Negate the Benefit of Up-front Cytoreduction in Advanced Ovarian Cancer?

Background:
The objective of the study was to determine if initial surgery (IS) or initial chemotherapy (IC) affects rates of optimal surgery and survival in a population with significant medical comorbidities.

Conclusions:
The achievement of optimal cytoreduction continues to be a significant predictor of survival, regardless of treatment approach. Patients selected for IS and in whom optimal cytoreduction was achieved had improvements in both progression-free survival and overall survival. However, the differences could not be explained by surgical effort alone as diabetes was independently associated with mortality.

Fifth Lilly Oncology on Canvas Art Competition Invites All Touched by Cancer to... -- U.S./deadline June 29th



Fifth Lilly Oncology on Canvas Art Competition Invites All Touched by Cancer to... -- INDIANAPOLIS, Feb. 9, 2012 /PRNewswire/ --

INDIANAPOLIS, Feb. 9, 2012 /PRNewswire/ --

Get your canvases, paintbrushes and cameras ready -- the subject is cancer and you are the storyteller. Lilly Oncology and the National Coalition for Cancer Survivorship (NCCS) today announced the launch of the 2012 Lilly Oncology On Canvas: Expressions of a Cancer Journey Art Competition and Exhibition. The biennial competition invites individuals from the United States and Puerto Rico, who were diagnosed with any type of cancer -- as well as their families, friends, caregivers and healthcare providers -- to express, through art and narrative, the life-affirming changes that give their cancer journeys meaning. Entries must be postmarked by June 29, 2012

abstract: Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors [Phase I and Clinical Pharmacology]



Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors [Phase I and Clinical Pharmacology]:

Purpose
The appropriate selection of patients for early clinical trials presents a major challenge. Previous analyses focusing on this problem were limited by small size and by interpractice heterogeneity. This study aims to define prognostic factors to guide risk-benefit assessments by using a large patient database from multiple phase I trials.

Patients and Methods
Data were collected from 2,182 eligible patients treated in phase I trials between 2005 and 2007 in 14 European institutions. We derived and validated independent prognostic factors for 90-day mortality by using multivariate logistic regression analysis.

Results
The 90-day mortality was 16.5% with a drug-related death rate of 0.4%. Trial discontinuation within 3 weeks occurred in 14% of patients primarily because of disease progression. Eight different prognostic variables for 90-day mortality were validated: performance status (PS), albumin, lactate dehydrogenase, alkaline phosphatase, number of metastatic sites, clinical tumor growth rate, lymphocytes, and WBC. Two different models of prognostic scores for 90-day mortality were generated by using these factors, including or excluding PS; both achieved specificities of more than 85% and sensitivities of approximately 50% when using a score cutoff of 5 or higher. These models were not superior to the previously published Royal Marsden Hospital score in their ability to predict 90-day mortality.

Conclusion
Patient selection using any of these prognostic scores will reduce non–drug-related 90-day mortality among patients enrolled in phase I trials by 50%. However, this can be achieved only by an overall reduction in recruitment to phase I studies of 20%, more than half of whom would in fact have survived beyond 90 days.

abstract: (Lynch Syndrome) Colorectal and Other Cancer Risks for Carriers and Noncarriers From Families With a DNA Mismatch Repair Gene Mutation: A Prospective Cohort Study [Epidemiology] multi-national study



 Blogger's Note: some stats deleted for ease of reading, see abstract (or paid subscription for full details; interesting stat on female breast cancer


Colorectal and Other Cancer Risks for Carriers and Noncarriers From Families With a DNA Mismatch Repair Gene Mutation: A Prospective Cohort Study [Epidemiology]:

Purpose
To determine whether cancer risks for carriers and noncarriers from families with a mismatch repair (MMR) gene mutation are increased above the risks of the general population.

Patients and Methods
We prospectively followed a cohort of 446 unaffected carriers of an MMR gene mutation (MLH1, n = 161; MSH2, n = 222; MSH6, n = 47; and PMS2, n = 16) and 1,029 their unaffected relatives who did not carry a mutation every 5 years at recruitment centers of the Colon Cancer Family Registry. For comparison of cancer risk with the general population, we estimated country-, age-, and sex-specific standardized incidence ratios (SIRs) of cancer for carriers and noncarriers.
Results
Over a median follow-up of 5 years, mutation carriers had an increased risk of

colorectal cancer (20.48),
endometrial cancer (30.62),  
ovarian cancer (18.81),
renal cancer (11.22),
pancreatic cancer ( 10.68), 
gastric cancer (9.78),  
urinary bladder cancer (9.51), and  
female breast cancer ( 3.95;).

We found no evidence of their noncarrier relatives having an increased risk of any cancer, including CRC (1.02).

Conclusion 
 We confirmed that carriers of an MMR gene mutation were at increased risk of a wide variety of cancers, including some cancers not previously recognized as being a result of MMR mutations, and found no evidence of an increased risk of cancer for their noncarrier relatives.

JCO abstract: Understanding Patients' Attitudes Toward Communication About the Cost of Cancer Care



 Blogger's Note: semantics - 'most'/'majority' requires language editing eg. majority 68%, most 59% (language bias?)

Understanding Patients' Attitudes Toward Communication About the Cost of Cancer Care

Abstract
Purpose: Recent publications have promoted physician-patient communication on cost as a means of decreasing overall spending and minimizing patients' financial burden in oncology. No study has assessed patients' perspectives on cost communication in oncology......

Results: Of the 771 patients approached, 256 responded (response rate, 33%). Most (68%) preferred to know about out-of-pocket costs before treatment. A majority (59%) wanted their physician to discuss these costs with them. Although 76% reported feeling comfortable discussing cost with their physician, 74% were amenable to discussing cost with someone other than their physician. Most patients did not consider out-of-pocket costs (57%) or the health care costs of the country (61%) in their decision making, nor did they believe their physician should (55%). Patients receiving active chemotherapy were less likely to want to discuss out-of-pocket costs with their physician (P = .035). 

Conclusion: Patients' comfort with and desire to discuss cancer costs exceed that of oncologists, suggesting a need to educate oncologists on this important topic. A patient's desire to understand treatment-associated cost does not equate with a desire for cost to influence medical decision making.

Caveat Oncologist: Clinical Findings and Consequences of Distributing Counterfeit Erythropoietin in the United States (Florida)



Caveat Oncologist: Clinical Findings and Consequences of Distributing Counterfeit Erythropoietin in the United States [Original Contributions]:

Purpose:
Counterfeit pharmaceuticals pose risks domestically. Because of their cost, cancer pharmaceuticals are vulnerable. We review findings from a domestic counterfeiting episode involving erythropoietin and outline anticounterfeiting recommendations for policy makers, patients, and health care professionals.

Countering the Misincentivization of Cancer Medicine by Real-Time Personal Professional Education (febrile neutropenia medications)



Countering the Misincentivization of Cancer Medicine by Real-Time Personal Professional Education [Cancer Center Business Summit]:

Purpose:
In the United States, public and private payer misincentivization of medical care and the invisibility of costs to the consumers of that care have conspired to create unsustainable growth in health care expenditure that undermines our economy, diminishes our productivity, and limits our international competitiveness. Cancer medicine provides a small yet salient example. On average, Medicare reimburses oncologists 6% above the average acquisition price for essential anticancer agents and supportive therapies. The costs of these agents vary across a stunning five orders of magnitude, from a few dollars to more than $400,000 per course of treatment. The profitability to providers varies across approximately four orders of magnitude, from cents to thousands of dollars per treatment. National guidelines (National Comprehensive Cancer Network [NCCN], American Society of Clinical Oncology [ASCO]) help providers select the most effective therapies without regard for cost.

Methods:
We created an oncologist-to-oncologist professional education program to help cancer physicians optimally use expensive long-acting white blood cell growth factors, in accordance with these national guidelines.

abstract: Factors Associated With Pain Among Ambulatory Patients With Cancer With Advanced Disease at a Comprehensive Cancer Center (Center for Patient Safety, Dana-Farber Cancer Institute)



Factors Associated With Pain Among Ambulatory Patients With Cancer With Advanced Disease at a Comprehensive Cancer Center

Conclusion:
Younger age, minority race, and recent onset of advanced disease are associated with severe pain among patients with cancer. Recognizing these high-risk groups could inform targeted interventions to address pain care in ambulatory patients with advanced cancer.

Lynch Syndrome: Don't Miss It (Transcript including slides))



Blogger's Opinion/Note:
guidelines indicate varying ages of screening depending on organ assuming there are screening mechanisms (eg. ovarian cancer has no screening for the general population however increased surveillance is possible for those at high risk,  albeit, ineffective; generally 25 yrs +;  'averages' are not helpful and therefore the urging of family history taking by primary/family care physicians, see NCCN guidelines for Lynch Syndrome which includes gene-specific details (eg. MLH1, MSH2/6, PMS2.....)

Lynch Syndrome: Don't Miss It (Transcript)

Clinical Implications

"Lynch syndrome is a genetic defect that has significant implications on the clinical side. A patient whose genetic testing is positive for Lynch syndrome has a likelihood of developing colon cancer that approaches 70% over his or her lifetime. The risk for uterine cancer is similar or a bit higher, and the risk for ovarian cancer is13%-15%. Almost certainly, these patients will have some type of cancer during their lifetime.

Metachronous cancers occur in 7%-10% of patients with Lynch syndrome. These patients present with one cancer, and typically in the course of a short period of time, another cancer develops. In patients with Lynch syndrome who have colon cancer, if you don't perform a subtotal colectomy because you didn't recognize that it was Lynch syndrome, the likelihood that the patient will develop a repeat colon cancer over 30 years (even in patients who are being screened) approaches 65%. This is not uncommon. A lot of these diagnoses are missed, and a secondary cancer develops."

"You need to start thinking about syndromic cancers because the relative risk is quite high. You need to be thinking about this in patients with early cancers -- not just colon cancer, but in uterine cancer and ovarian cancer as well." (Blogger's Note: and others including pancreatic, stomach, ureter, renal, bilary tract, gallbladder.....see slides)

" If you look at colon cancer in Lynch syndrome, the average age of onset is earlier (45 years) and some patients may be in their 20s. For sporadic uterine cancer, the average age is approximately 60 years, but in Lynch syndrome, it is shifted by a decade, to 50 years. When you see these cancers in a younger patient, the bell should go off and you should start thinking about Lynch syndrome and doing the appropriate testing."

"It is important to think about extracolonic cancers in these patients and to start to put the dots together because we are missing the boat on a lot of these syndromic cancers. It's not a zebra; it's 2%-3% of the patients who are presenting with cancer. We need to think outside the box. Even if you are not a gastroenterologist, include the colon when you see syndromic related cancers of the uterus, ovary, small bowel, or stomach."

Future Science - abstract: Targeted cancer therapy: giving histone deacetylase inhibitors



Future Science - Future Medicinal Chemistry - 4(4):505 - Summary

Review
Abstract

Targeted cancer therapy: giving histone deacetylase inhibitors


"Histone deacetylase inhibitors (HDACis) have now emerged as a powerful new class of small-molecule therapeutics acting through the regulation of the acetylation states of histone proteins (a form of epigenetic modulation) and other non-histone protein targets. Over 490 clinical trials have been initiated in the last 10 years, culminating in the approval of two structurally distinct HDACis – SAHA (vorinostat, Zolinza™) and FK228 (romidepsin, Istodax™). 

However, the current HDACis have serious limitations, including ineffectively low concentrations in solid tumors and cardiac toxicity, which is hindering their progress in the clinic. Herein, we review the primary paradigms being pursued to overcome these hindrances, including HDAC isoform selectivity, localized administration, and targeting cap groups to achieve selective tissue and cell type distribution."

Future Science - Abstract: EGFR/HER-targeted therapeutics in ovarian cancer



Blogger's Note: this is a subscription based ($$$) journal

Future Science - Future Medicinal Chemistry - 4(4):447 - Summary


Review

EGFR/HER-targeted therapeutics in ovarian cancer

"Despite decades of research and evolving treatment modalities, survival among patients with epithelial ovarian cancer has improved only incrementally.
During this same period, the development of biologically targeted therapeutics has improved survival for patients with diverse malignancies.
Many of these new drugs target the human epidermal growth factor receptor (EGFR/HER/ErbB) family of tyrosine kinases, which play a major role in the etiology and progression of many carcinomas, including epithelial ovarian cancer. While several HER-targeted therapeutics are US FDA approved for the treatment of various malignancies, none have gained approval for the treatment of ovarian cancer.
Here, we review the published literature on HER-targeted therapeutics for the treatment of ovarian cancer, including novel HER-targeted therapeutics in various stages of clinical development, as well as the challenges that have limited the use of these inhibitors in clinical settings."

Cochrane Review: Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer (abstract)



Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer [Cochrane Database Syst Rev. 2012]


Cochrane Database Syst Rev. 2012 Mar 14;3:CD004706.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Abstract

BACKGROUND:

Epithelial ovarian cancer is diagnosed in 4500 women in the UK each year of whom 1700 will ultimately die of their disease.Of all cases 10% to 15% are diagnosed early when there is still a good possibility of cure. The treatment of early stage disease involves surgery to remove disease often followed by chemotherapy. The largest clinical trials of this adjuvant therapy show an overall survival (OS) advantage with adjuvant platinum-based chemotherapy but the precise role of this treatment in subgroups of women with differing prognoses needs to be defined.

OBJECTIVES:

To systematically review the evidence for adjuvant chemotherapy in early stage epithelial ovarian cancer to determine firstly whether there is a survival advantage of this treatment over the policy of observation following surgery with chemotherapy reserved for treatment of disease recurrence, and secondly to determine if clinical subgroups of differing prognosis based on histological sub-type, or completeness of surgical staging, have more or less to gain from chemotherapy following initial surgery.

SELECTION CRITERIA:

We selected randomised clinical trials that met the inclusion criteria set out based on the populations, interventions, comparisons and outcome measures.

MAIN RESULTS:

Five randomised controlled trials (RCTs), enrolling 1277 women, with a median follow-up of 46 to 121 months, met the inclusion criteria. Four trials were included in the meta-analyses and we considered them to be at a low risk of bias. Meta-analysis of five-year data from three trials indicated that women who received adjuvant platinum-based chemotherapy had better overall survival (OS) than those who did not (1008 women; hazard ratio (HR) 0.71; 95% confidence interval (CI) 0.53 to 0.93). Likewise, meta-analysis of five-year data from four trials indicated that women who received adjuvant chemotherapy had better progression-free survival (PFS) than those who did not (1170 women; HR 0.67; 95% CI 0.53 to 0.84). The trials included in these meta-analyses gave consistent estimates of the effects of chemotherapy. In addition, these findings were robust over time (10-year PFS: two trials, 925 women; HR 0.67; 95% CI 0.54 to 0.84).
Subgroup analysis suggested that women who had optimal surgical staging of their disease were unlikely to benefit from adjuvant chemotherapy (HR for OS 1.22; 95% CI 0.63 to 2.37; two trials, 234 women) whereas those who had sub-optimal staging did (HR for OS 0.63; 95% CI 0.46 to 0.85; two trials, 772 women). One trial showed a benefit from adjuvant chemotherapy among women at high risk (HR for OS 0.48; 95% CI 0.32 to 0.72) but not among those at low/medium risk (HR for OS 0.95; 95% CI 0.54 to 1.66).
However, these subgroup findings could be due to chance and should be interpreted with caution.

AUTHORS' CONCLUSIONS:

Adjuvant platinum-based chemotherapy is effective in prolonging the survival of the majority of patients who are assessed as having early (FIGO stage I/IIa) epithelial ovarian cancer. However, it may be withheld from women in whom there is well-differentiated encapsulated unilateral disease (stage 1a grade 1) or those with comprehensively staged Ib, well or moderately differentiated (grade 1/2) disease. Others with unstaged early disease or those with poorly differentiated tumours should be offered chemotherapy.

A pragmatic approach may be necessary in clinical settings where optimal staging is not normally performed/achieved. In such settings, adjuvant chemotherapy may be withheld from those with encapsulated stage Ia grade 1 serous and endometrioid carcinoma and offered to all others with early stage disease.

Friday, March 16, 2012

Current Drug Shortages: Paclitaxel (Taxol) Injection (updated)



Current Drug Shortages: Paclitaxel Injection (updated):

Hospira product 30 mg/5 mL vial (NDC 0409-0342-09): ample levels of inventory to support market demand. Product 300 mg/50 mL vial (NDC 0409-0342-50): ample levels of inventory to support market demand. Product 100 mg/16.7 mL vial (NDC 0409-0342-22): next delivery April. Please check with your wholesaler for available inventory. Teva has 30 mg/ 5 ml vial on backorder until April 2012. All other presentations are available with ample inventory.